COX → Prostaglandins — research review 1

...and that's a key pathway for pain. Cyclooxygenase, or COX, enzymes create prostaglandins, which are molecules that sensitize nerves and fuel inflammation. When we talk about aging and mortality in this context, it’s a two-sided coin.

Right, one side being the impact of unrelieved chronic pain itself. We know chronic inflammation is a major predictor of all-cause mortality. For instance, a study in Experimental Gerontology in 2015 found that serum IL-6, a pro-inflammatory cytokine, showed a robust dose-response relationship with all-cause mortality in the oldest old.

And the COX-prostaglandin pathway definitely feeds into that inflammatory cascade. Beyond general inflammation, there's direct evidence linking chronic pain to accelerated biological aging. A GeroScience paper from 2025 showed painful diabetic neuropathy is associated with accelerated epigenetic aging and telomere shortening compared with painless neuropathy.

So, the unrelieved pain, acting through this inflammatory system, seems to accelerate our biological clock. But then, on the other side of that coin, are the drugs that target this pathway.

Exactly. Many common pain relievers block COX enzymes, reducing prostaglandin production. They're incredibly effective for acute pain and inflammation, genuinely benefiting millions. But these medications, particularly with long-term or high-dose use, carry their own risks for cardiovascular events, kidney issues, and gastrointestinal bleeding.

So, it's not that the COX-prostaglandin pathway itself 'causes' death, but rather the consequences of chronic, unrelieved pain acting through this system, and the potential risks associated with the medications used to manage it. What we still don't fully understand is the precise balance for individuals—how to mitigate accelerated aging from chronic pain without increasing other risks with long-term drug use.